Related Experiment Video

Updated: Jul 1, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

[Prognostic scores of cirrhosis]

Isabel Campos-Varela1, Lluís Castells

  • 1Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Unidad de Hepatología, Servicio de Medicina Interna, Hospital General Universitari Vall d'Hebron, Barcelona, España.

Gastroenterologia Y Hepatologia
|September 12, 2008
PubMed

Insights

The Child-Pugh classification and model for end-stage liver disease (MELD) are key prognostic models for liver cirrhosis. While MELD is now preferred for liver transplantation, it has limitations in representing certain conditions.

Area of Science:

  • Hepatology and Gastroenterology
  • Clinical Prognostic Modeling
  • Liver Disease Assessment

Context:

  • Liver cirrhosis necessitates accurate prognostic models for disease severity and survival estimation.
  • The Child-Pugh classification historically stratified patients for liver surgery and transplantation.
  • The model for end-stage liver disease (MELD) has largely replaced Child-Pugh due to objective variables.

Purpose:

  • To review the utility and limitations of prognostic scoring systems in liver cirrhosis.
  • To highlight the shift from Child-Pugh to MELD in clinical practice.
  • To identify areas where MELD may not fully capture disease complexity.

Summary:

  • Prognostic models like Child-Pugh and MELD are crucial in managing liver cirrhosis.
  • MELD, utilizing objective variables, is now the standard for liver transplant organ allocation.
  • MELD's limitations include underrepresentation of specific transplant indications and comorbidities.

Impact:

  • Improved understanding of MELD's strengths and weaknesses in liver disease management.
  • Informing potential refinements to prognostic models for better patient stratification.
  • Guiding clinical decisions in liver transplantation and patient care.

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...